Refactoring Legacy JavaScript Code to Use Classes: The Good, The Bad and The Ugly

JavaScript systems are becoming increasingly complex and large. To tackle the challenges involved in implementing these systems, the language is evolving to include several constructions for programming- in-the-large. For example, although the language is prototype-based, the latest JavaScript standard, named ECMAScript 6 (ES6), provides native support for implementing classes. Even though most modern web browsers support ES6, only a very few applications use the class syntax. In this paper, we analyze the process of migrating structures that emulate classes in legacy JavaScript code to adopt the new syntax for classes introduced by ES6. We apply a set of migration rules on eight legacy JavaScript systems. In our study, we document: (a) cases that are straightforward to migrate (the good parts); (b) cases that require manual and ad-hoc migration (the bad parts); and (c) cases that cannot be migrated due to limitations and restrictions of ES6 (the ugly parts). Six out of eight systems (75%) contain instances of bad and/or ugly cases. We also collect the perceptions of JavaScript developers about migrating their code to use the new syntax for classes.Comment: Paper accepted at 16th International Conference on Software Reuse (ICSR), 2017; 16 page

Online parameter identification of facet growth kinetics in crystal morphology population balance models

AbstractParticle shape plays an important role in many industrial applications since it can have significant impact on both, processability of particles as well as the properties of the final product. For this reason modeling of the corresponding production process is crucial for developing efficient process optimization and control strategies. The shape evolution of crystals on the process scale can be described conveniently within the framework of morphological population balance modeling. In order of being a reliable tool for the prediction of the crystal shape distribution during the production process as well as for the design of suitable control and optimal production strategies, the models require the estimation of several parameters characterizing the growth rates of the different crystal facets. This is particularly challenging due to the infinite dimensional state space of the models. In this contribution online parameter estimation for the growth rates of L-glutamic acid cooling crystallization is presented. Using a Lyapunov-based approach the parameter adaption laws are computed directly from the infinite dimensional problem formulation. It will be shown that a reasonably fast convergence of the parameter estimates can be achieved even in the presence of measurement noise using appropriate filters

Safety of higher dosages of Viscum album L. in animals and humans - systematic review of immune changes and safety parameters

<p>Abstract</p> <p>Background</p> <p><it>Viscum album </it>L extracts (VAE, mistletoe) and isolated mistletoe lectins (ML) have immunostimulating properties and a strong dose-dependent cytotoxic activity. They are frequently used in complementary cancer treatment, mainly to improve quality of life, but partly also to influence tumour growth, especially by injecting VAE locally and in high dosage. The question is raised whether these higher dosages can induce any harm or immunosuppressive effects.</p> <p>Methods</p> <p>Systematic review of all experiments and clinical studies investigating higher dosages of VAE in animals and humans (<it>Viscum album </it>> 1 mg in humans corresponding to > 0.02 mg/kg in animals or ML > 1 ng/kg) and assessing immune parameters or infections or adverse drug reactions.</p> <p>Results</p> <p>69 clinical studies and 48 animal experiments reported application of higher doses of VAE or ML and had assessed immune changes and/or harm. In these studies, <it>Viscum album </it>was applied in dosages up to 1500 mg in humans and 1400 mg/kg in animals, ML was applied up to 6.4 μg/kg in humans and in animals up to 14 μg/kg subcutaneously, 50 μg/kg nasally and 500 μg/kg orally. A variety of immune parameters showed fluctuating or rising outcomes, but no immunosuppressive effect. Side effects consisted mainly of dose-dependent flu-like symptoms (FLS), fever, local reactions at the injection site and various mild unspecific effects. Occasionally, allergic reactions were reported. After application of high doses of recombinant ML, reversible hepatotoxicity was observed in some cases.</p> <p>Conclusions</p> <p>Application of higher dosages of VAE or ML is not accompanied by immunosuppression; altogether VAE seems to exhibit low risk but should be monitored by clinicians when applied in high dosages.</p